BCCA7693 / adMare BioInnovations, BC Cancer Agency - LARVOL DELTA

BCCA7693 - A novel, orally bioavailable DNA-PK inhibitor demonstrates efficacy with targeted therapeutics by inhibiting the development of acquired resistance (AACR 2026) - "In mutated KRAS, BRAF and BRCA models, BCCA7693 demonstrated efficacy with targeted therapeutics, decreasing tumour cell survival during replicative stress and blocking the development of acquired resistance with trametinib, adagrasib, dabrafenib, afatinib, olaparib and the pol-θ inhibitor ART558. In contrast to conventional DSB inducing radio- and chemotherapy, murine studies with BCCA7693 did not result in increased toxicity/weight loss for combination treatments with the molecular targeted therapeutics, suggesting the potential for an additional clinical application of this DSB repair inhibitor. BCCA7693, shows potential for combination with a range of targeted cancer therapeutics."

Clinical • Late-breaking abstract • Preclinical • Oncology • BRAF • BRCA • KRAS